How Microbiome-based Therapeutics May Impact Treatment Landscape for C. Diff Infection, Recurrent C. Diff Infection

Name: How Microbiome-based Therapeutics May Impact Treatment Landscape for C. Diff Infection, Recurrent C. Diff Infection
Uploaded: 2021-12-11T17:00:00.000Z
Description: Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, discussed how microbiome-based therapeutics may impact the current treatment landscape for C. diff infection and recurrent C. diff infection.

December 11, 2021

Video

Conference|ASHP Midyear Clinical Meeting and Exhibition - American Society of Health System Pharmacists Midyear Clinical Meeting and Exhibition

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, discussed how microbiome-based therapeutics may impact the current treatment landscape for C. diff infection and recurrent C. diff infection.

Pharmacy Times interviewed Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, on her presentation at the American Society of Health-System Pharmacists 2021 Midyear Clinical Meeting on whether the power of the microbiome can be unlocked to break the cycle of recurrent Clostridioides difficile (C. diff) infection.

During the interview, Chopra discussed how microbiome-based therapeutics may impact the current treatment landscape for C. diff infection and recurrent C. diff infection.